Mairs & Power Inc. Has $9.56 Million Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Mairs & Power Inc. lessened its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 15.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,189 shares of the company’s stock after selling 5,902 shares during the period. Mairs & Power Inc.’s holdings in Medpace were worth $9,560,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. RiverPark Advisors LLC acquired a new position in shares of Medpace during the fourth quarter worth about $26,000. Contravisory Investment Management Inc. bought a new stake in Medpace in the 4th quarter valued at approximately $26,000. GAMMA Investing LLC acquired a new position in Medpace during the 4th quarter worth approximately $30,000. McGlone Suttner Wealth Management Inc. acquired a new stake in shares of Medpace in the fourth quarter valued at approximately $33,000. Finally, Principal Securities Inc. acquired a new stake in shares of Medpace in the fourth quarter valued at approximately $68,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

MEDP has been the subject of several recent research reports. UBS Group raised shares of Medpace from a “neutral” rating to a “buy” rating and raised their target price for the company from $282.00 to $452.00 in a research report on Thursday, February 15th. Deutsche Bank Aktiengesellschaft started coverage on Medpace in a report on Monday, March 18th. They issued a “hold” rating and a $395.00 price objective for the company. Guggenheim upped their target price on Medpace from $453.00 to $464.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. StockNews.com downgraded Medpace from a “buy” rating to a “hold” rating in a research note on Friday, June 7th. Finally, TD Cowen initiated coverage on Medpace in a report on Wednesday, May 29th. They issued a “buy” rating and a $452.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Medpace has an average rating of “Moderate Buy” and an average price target of $443.14.

Medpace Stock Up 1.7 %

Shares of MEDP traded up $6.57 during trading hours on Wednesday, hitting $403.74. The company had a trading volume of 201,270 shares, compared to its average volume of 232,327. The firm has a market cap of $12.51 billion, a price-to-earnings ratio of 41.47, a PEG ratio of 2.01 and a beta of 1.39. The business has a fifty day moving average of $393.93 and a 200-day moving average of $356.59. Medpace Holdings, Inc. has a 12 month low of $214.32 and a 12 month high of $421.00.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, topping analysts’ consensus estimates of $2.45 by $0.75. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The company had revenue of $511.00 million during the quarter, compared to the consensus estimate of $512.39 million. During the same quarter last year, the firm earned $2.27 earnings per share. The company’s revenue was up 17.7% on a year-over-year basis. On average, equities analysts expect that Medpace Holdings, Inc. will post 11.29 EPS for the current fiscal year.

Insiders Place Their Bets

In other Medpace news, VP Susan E. Burwig sold 102 shares of the business’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $403.00, for a total transaction of $41,106.00. Following the sale, the vice president now owns 15,181 shares of the company’s stock, valued at $6,117,943. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, VP Susan E. Burwig sold 102 shares of Medpace stock in a transaction on Friday, March 15th. The shares were sold at an average price of $403.00, for a total transaction of $41,106.00. Following the transaction, the vice president now owns 15,181 shares in the company, valued at $6,117,943. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO August J. Troendle sold 5,695 shares of the firm’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $395.49, for a total value of $2,252,315.55. Following the transaction, the chief executive officer now directly owns 654,656 shares of the company’s stock, valued at $258,909,901.44. The disclosure for this sale can be found here. Insiders have sold 29,973 shares of company stock worth $11,960,425 over the last ninety days. Corporate insiders own 20.30% of the company’s stock.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.